再程放疗联合同期及维持纳武利尤单抗治疗局部复发不可手术头颈鳞癌的单中心队列研究
结果显示中位总生存11个月,12个月生存率50%,中位局部无进展生存8个月,6和12个月局部无进展生存率分别为60%和30%,疗效不劣于同期顺铂再程放疗患者,未出现意外毒性。
要点
- 再程放疗联合同期及维持纳武利尤单抗可行,未出现意外放疗相关毒性。
- 中位OS 11个月,12个月OS率50%;中位LPFS 8个月,6和12个月LPFS率60%和30%。
- CRP升高、血红蛋白降低、NLR升高及RPA分级较高与LPFS受损相关。
核心结论
- 再程放疗联合纳武利尤单抗治疗局部复发头颈鳞癌可行,未出现意外毒性,可能为不适合挽救手术的经治患者提供有效选择。
研究设计与样本
- 患者接受60 Gy/30次再程放疗联合同期及维持纳武利尤单抗治疗,并与倾向性评分匹配后接受同期顺铂再程放疗的患者进行比较。
主要发现
- 所有患者完成再程放疗,纳武利尤单抗中位疗程数12(范围3-38)。
- 12个月OS率50%,中位OS 11(范围2-23)个月;6和12个月LPFS率分别为60%和30%,中位LPFS 8(范围2-19)个月。
- OS和LPFS不劣于同期顺铂再程放疗患者,未出现意外放疗相关毒性。
- 4例患者发生任何级别免疫相关不良事件,其中2例为3级毒性;1例患者在再程放疗后3周内死亡。
- CRP较高(p=0.004)、血红蛋白较低(p=0.029)、中性粒细胞/淋巴细胞比值较高(p=0.004)与LPFS受损相关;RPA分级较高与LPFS(p=0.022)和OS(p=0.024)受损相关。
关键数值与推荐
- 再程放疗剂量为60 Gy分30次,联合同期及维持纳武利尤单抗。
- 中位纳武利尤单抗疗程数12(范围3-38)。
- 12个月OS率50%,中位OS 11(范围2-23)个月。
- 6和12个月LPFS率分别为60%和30%,中位LPFS 8(范围2-19)个月。
- CRP(p=0.004)、血红蛋白(p=0.029)、NLR(p=0.004)及RPA分级(LPFS p=0.022,OS p=0.024)与预后相关。
临床怎么用
- 对于既往接受过放疗后局部复发且不适合挽救手术的头颈鳞癌患者,可考虑再程放疗联合同期及维持纳武利尤单抗。
- 治疗前应评估CRP、血红蛋白、中性粒细胞/淋巴细胞比值及RPA分级,以识别可能获益有限的患者。
- 治疗期间需监测免疫相关不良事件,本研究中出现3级毒性及1例早期死亡。
局限性
- 与顺铂组比较采用倾向性评分匹配,但样本量小。
- 随访时间及数据收集受限,结论需更大样本前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rate of loco-regional recurrences for locally advanced head and neck squamous cell carcinoma (HNSCC) following standard treatment reaches up to 50%, accompanied by a probability of 20% to develop a second primary tumor in the head and neck region. METHODS: Ten patients with inoperable, in-field recurrence of HNSCC following previous primary or adjuvant radiotherapy (RT) in combination with concurrent platinum-based chemotherapy were re-irradiated with 60 Gray in 30 fractions between December 2017 and January 2020 with concurrent and maintenance nivolumab administration. Data were retrospectively collected and compared with patients who underwent re-irradiation (ReRT) with concurrent cisplatin following propensity score matching (PSM). Local progression-free survival (LPFS) and overall survival (OS) were visualized using Kaplan-Meier method (log-rank test). RESULTS: All patients completed ReRT. Median number of applied courses of nivolumab was 12 (range, 3-38). OS rate was 50% at 12 months and the median OS was 11 (range, 2-23) months. Six and 12 month LPFS rates were 60% and 30%, respectively. Median LPFS was 8 (range, 2-19) months. OS and LPFS rates were not inferior to those of patients treated with concurrent cisplatin. No unexpected radiation-related toxicity occurred. A total of four patients developed any-grade immune-related adverse events of which two presented with grade 3 toxicities. One patient died within 3 weeks after ReRT. Higher blood levels of CRP (p = 0.004), lower levels of hemoglobin (p = 0.029) and higher neutrophil/lymphocyte ratio (p = 0.004) were associated with impaired LPFS. Higher recursive portioning analysis (RPA) class was associated with impaired LPFS (p = 0.022) and OS (p = 0.024). CONCLUSION: The combination of ReRT and nivolumab for locally recurrent HNSCC was feasible without occurrence of unexpected toxicities. Combined radioimmunotherapy might offer an effective treatment option for carefully selected pre-irradiated patients ineligible for salvage surgery.
引用
- Altay-Langguth A, Balermpas P, Brandts C, et al. Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. Clin Transl Radiat Oncol. 2021. PMID: 33889760. doi:10.1016/j.ctro.2021.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。